| Drug ID: | Drug199 |
|---|---|
| Drug Name: | Pegunigalsidase alfa |
| CID: | 121488171 |
| DrugBank ID: | DB14992 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05710692, , NCT06095713, , NCT03566017, , NCT06663358, , NCT03614234, , NCT04552691, , NCT02795676, , NCT03180840, , NCT01981720, , NCT03018730, , NCT01678898, , NCT02921620 |
| Molecular Formula: | C24H44N6O9 |
| Molecular Weight: | 560.6 g/mol |
| Isomeric SMILES: | C(CCNC(=O)CCC(=O)NCCOCCNC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N)C[C@@H](C(=O)O)N |
| Synonyms: | PRX-102; pegunigalsidase-alfa; Pegunigalsidase alfa; Q27270744 |
| Phase 0: | 0 |
| Phase 1: | 2 |
| Phase 2: | 5 |
| Phase 3: | 9 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1403 | 121488171 | Pegunigalsidase-alfa | 2717 | GLA | Homo sapiens (human) | Modulator |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations